Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil

Abstract

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution) Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

Hidradenitis Suppurativa: Molecular Etiology, Pathophysiology, and Management—A Systematic Review

“…For mild HS, topical treatments are frequently employed, with systematic therapies and surgical approaches subsequently added with increased extension and severity of HS lesions [14]. Common topical antibiotics used for HS include clindamycin, erythromycin, and gentamicin [32]. Topical antibiotics such as clindamycin have been shown to decrease HS lesions through a 3-month randomized controlled trial but were limited by the exclusion of HS staging [13].…”

Cerebral Tuberculosis After Therapy With Adalimumab for Hidradenitis Suppurativa: A Rare Case

“…The highest occurrence of HS is observed in patients aged between 18 and 44 years [ 4 ]. Management options include a combination of medical therapies, such as antibiotics, immunosuppressants, and biologics [ 5 , 6 ], associated with lifestyle modifications, as well as surgical interventions, including incision and drainage, wide local excision, or laser therapy [ 5 ]. The prognosis of HS can vary widely among individuals, with some experiencing chronic, relapsing disease, while others achieve prolonged periods of remission [ 1 , 2 ].…”

“…Adalimumab, a TNF-α inhibitor, has shown promise in the treatment of HS, a debilitating chronic skin condition [5]. By targeting the pro-inflammatory cytokine TNF-α, adalimumab can help mitigate the inflammatory processes associated with HS, reducing the frequency and severity of painful abscesses, sinus tracts, and scarring [5,6]. It is used for moderate to severe HS cases that are refractory to conventional therapies [5], demonstrating the potential to improve quality of life and induce long-term disease remission in some individuals [5][6][7][8][9].…”

“…By targeting the pro-inflammatory cytokine TNF-α, adalimumab can help mitigate the inflammatory processes associated with HS, reducing the frequency and severity of painful abscesses, sinus tracts, and scarring [5,6]. It is used for moderate to severe HS cases that are refractory to conventional therapies [5], demonstrating the potential to improve quality of life and induce long-term disease remission in some individuals [5][6][7][8][9]. Adalimumab is an important therapeutic tool in the management of this challenging condition; however, like other biologics, its use comes with considerations for potential side effects and increases susceptibility to severe and opportunistic infections, including tuberculosis (TB) [6,7].…”

Navigating the Multidimensional Impact of Living with Hidradenitis Suppurativa: An In-Depth Netnographic Study on Social Media Platforms

“…HS presents a unique set of challenges for patients in Brazil, a diverse country characterized by vast regional differences in healthcare access and quality, socioeconomic disparities, and cultural beliefs and practices related to health and illness [ 12 , 13 ]. Previous studies on HS in Brazil have primarily focused on clinical aspects such as disease prevalence, symptomatology, and treatment modalities, thereby leaving a gap in understanding the lived experiences of patients [ 8 , 12 , 14 , 15 ].…”